Bispecific T cell Engagers Virtual Workshop Schedule

Bispecific T cell Engagers Virtual Workshop Schedule

Two-Day Program Sept. 30–Oct. 1, 2021

View Enduring Materials Enduring materials are now open access. On-demand enduring materials are available as permitted by presenters. Indicates this content is not available on-demand.
Thursday, Sept. 30, 2021 *All times are Eastern Daylight Time.
Interrogating the Tumor-Specific Surfaceome for Immune Targeting and Bispecific T cell Engagers Workshops Overlapping Panel Discussion
Time:	1:55 – 2:50 p.m. EDT
Length:	55 minutes
Co-Chairs:	Daniel S. Chen, MD, PhD Avery D. Posey Jr., PhD – University of Pennsylvania School of Medicine
1:55 p.m.	Introduction Avery D. Posey Jr., PhD – University of Pennsylvania School of Medicine
2:00 p.m.	Panel Discussion Daniel S. Chen, MD, PhD Carl H. June, MD – University of Pennsylvania Pamela Holland, PhD – Alpine Immune Sciences Guido Kroemer, MD, PhD – Institute Gustave Roussy Loretta J. Nastoupil, MD – The University of Texas MD Anderson Robert D. Schreiber, PhD – Washington University School of Medicine
2:50 p.m.	Break
Opening Remarks
Time:	3:00 – 3:10 p.m. EDT
Length:	10 minutes
Organizer:	Elizabeth Budde, MD, PhD – City of Hope
Session I: CD8 T cell Biology and Function
Time:	3:10 – 4:10 p.m. EDT
Length:	60 minutes
Moderator:	Elizabeth Budde, MD, PhD – City of Hope
3:10 p.m.	Defining Exhausted CD8 T cells E. John Wherry, PhD – University of Pennsylvania
3:30 p.m.	Modulating force-mediated extracellular TCR-CD3 interaction to identify new immunotherapy targets Michelle Krogsgaard, PhD – New York University School of Medicine
3:50 p.m.	Panel Discussion Michelle Krogsgaard, PhD – New York University School of Medicine E. John Wherry, PhD – University of Pennsylvania
Session II: TCE Design Concepts
Time:	4:10 – 5:30 p.m. EDT
Length:	80 minutes
Moderator:	Daniel S. Chen, MD, PhD
4:10 p.m.	T-cell Engagers: Selection of Epitope and Affinity for the Tumor Associated Protein Diego Ellerman, PhD– Genentech
4:30 p.m.	CD3 Epitope and CD3 Affinity John Williams, PhD – City of Hope
4:50 p.m.	T-cell redirection plus targeted costimulation using engineered bispecific antibodies and fusion proteins: An off-the-shelf alternative for the treatment of solid and hematologic tumors Pablo Umana, PhD – Roche Glycart AG
5:10 p.m.	Panel Discussion Diego Ellerman, PhD– Genentech Pablo Umana, PhD – Roche Glycart AG John Williams, PhD – City of Hope
5:30 p.m.	Break
Session III: Clinical Data from TCE Studies
Time:	5:40 – 7:00 p.m. EDT
Length:	80 minutes
Moderator:	James L. Gulley, MD, PhD, FACP – National Cancer Institute
5:40 p.m.	Acapatamab, a PSMA-targeted BiTE® Immune Therapy for mCRPC Julie Bailis, PhD – Amgen
6:00 p.m.	IgG Bispecifics Charles Drake, MD, PhD – Columbia University Medical Center
6:20 p.m.	IgM Bispecifics Bruce Keyt, PhD – IGM Biosciences, Inc.
6:40 p.m.	Panel Discussion Julie Bailis, PhD – Amgen Charles Drake, MD, PhD – Columbia University Medical Center Bruce Keyt, PhD – IGM Biosciences, Inc.
Closing Remarks
Time:	7:00 – 7:05 p.m. EDT
Length:	5 minutes
Organizer:	Elizabeth Budde, MD, PhD – City of Hope
7:05 p.m.	Adjourn

Friday, Oct. 1, 2021 *All times are Eastern Daylight Time.
Opening Remarks
Time:	10:00 – 10:05 a.m. EDT
Length:	5 minutes
Organizer:	James L. Gulley, MD, PhD, FACP – National Cancer Institute
Session I: TCE Predictive Markers and TCE Resistance or Escape
Time:	10:05 – 11:05 a.m. EDT
Length:	60 minutes
Moderator:	Elizabeth Budde, MD, PhD – City of Hope
10:05 a.m.	TAA Expression Level and Loss Terry Fry, MD – University of Colorado School of Medicine
10:25 a.m.	T cell Function and State Genevive Hernandez, PhD – IGM Biosciences, Inc.
10:45 a.m.	Panel Discussion Terry Fry, MD – University of Colorado School of Medicine Genevive Hernandez, PhD – IGM Biosciences, Inc.
Session II: TCE as Cancer Immunotherapy and Combinations
Time:	11:05 a.m. – 12:45 p.m. EDT
Length:	100 minutes
Moderator:	Daniel S. Chen, MD, PhD
11:05 a.m.	Co-stimulatory molecules Bernard A. Fox, PhD – Earle A. Chiles Research Institute
11:25 a.m.	Cytokines Rafi Ahmed, PhD – Emory University
11:45 a.m.	TCE as immunotherapy and in combination with checkpoints Daniel S. Chen, MD, PhD
12:15 p.m.	Panel Discussion Rafi Ahmed, PhD – Emory University Daniel S. Chen, MD, PhD Bernard A. Fox, PhD – Earle A. Chiles Research Institute
Break
Time:	12:45 – 1:05 p.m. EDT
Length:	20 minutes
Session III: Lessons Learned from CART
Time:	1:05 – 2:05 p.m. EDT
Length:	60 minutes
Moderator:	James L. Gulley, MD, PhD, FACP – National Cancer Institute
1:05 p.m.	Cytokine Release Syndrome and ICANS: What we have learned from CAR T-cell Therapy Nirali Shah, MD, MHSc – National Institutes of Health
1:25 p.m.	CART vs TCE Pros/Cons/Compare & Contrast Elizabeth Budde, MD, PhD – City of Hope
1:45 p.m.	Panel Discussion Elizabeth Budde, MD, PhD – City of Hope Nirali Shah, MD, MHSc – National Institutes of Health

Session IV: Clincal Concepts – (clinical use and biological impact)
Time:	2:05 – 3:25 p.m. EDT
Length:	80 minutes
Moderator:	Elizabeth Budde, MD, PhD – City of Hope
2:05 p.m.	Step-up Dosing, SQ and Dose Titration Loretta J. Nastoupil, MD – The University of Texas MD Anderson Cancer Center
2:25 p.m.	Steroids and Tocilizumab Pat Brown, MD – Johns Hopkins University
2:45 p.m.	MOA & efficacy drivers of T cell bispecifics Teemu Junttila, PhD – Genentech
3:05 p.m.	Panel Discussion Pat Brown, MD – Johns Hopkins University Teemu Junttila, PhD – Genentech Loretta J. Nastoupil, MD –The University of Texas MD Anderson Cancer Center
Closing Remarks
Time:	3:25 – 3:35 p.m. EDT
Length:	10 minutes
Organizer:	Daniel S. Chen, MD, PhD
3:35 p.m.	Adjourn

Questions?

If you have questions about this program, please contact the SITC Education team

Program Access

Registrants will receive a link to access the virtual platform before the program.

Back to...

Bispecific Workshop Homepage

Bispecific T cell Engagers Virtual Workshop Schedule

Bispecific T cell Engagers Virtual Workshop Schedule

Questions?

Program Access

Back to...

Membership Links

Get Involved